SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
November 26, 2001
-----------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
------------------------------ ------- --------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
--------------------------------------
(Address of principal executive offices)
(631) 962-2000
--------------------------------------------------
(Registrant's telephone number, including area code)
N/A
-----------------------------
(Former name or former address,
if changed since last report.)
ITEM 5. OTHER EVENTS
On November 26, 2001, OSI Pharmaceuticals, Inc., a Delaware corporation
(the "Company") signed an agreement to acquire certain assets related to the
oncology business of Gilead Sciences, Inc., (Nasdaq: GILD), a Delaware
corporation, for $130 million in cash and $40 million in shares of the Company's
common stock. Details regarding the transaction are contained in the Company's
press release, dated November 26, 2001, which is attached as Exhibit 99 and
incorporated herein by reference.
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
99 Press release, dated November 26, 2001.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 11, 2001 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
99 Press release, dated November 26, 2001.